Mindestbestellung 120 EUR Kostenlose Lieferung ab 250 EUR Bereit zur Abholung dead drop: in 5 Min. abholen Kostenloser Versand ab 250 EUR Aktionen

Substanzen · Phenethylamin-Derivate

4F-MPH

C14H18FNO2 CAS 1354631-33-6 Nur für analytische Forschungszwecke — nicht für den menschlichen Verzehr
Bevorzugter Name
4F-MPH
IUPAC-Name
methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate
CAS-Nummer der Stammverbindung (Referenz)
1354631-33-6
Summenformel
C14H18FNO2
Molekulargewicht
251.3 g/mol
InChIKey
XISBAJBPDVRSPG-CHWSQXEVSA-N
PubChem
CID 52944002
Quelle
PubChem
Geprüfte Synonyme und Katalogkürzel
4-Fluoromethylphenidate 4FMPH 4F MPH threomethylphenidate-4F

Passende Artikel im aktuellen Shop-Katalog

Geprüftes Pharmakologie- & Toxikologie-Dossier

4F-MPH

Stimulant (dopamine/norepinephrine reuptake inhibitor) Ring-fluorinated phenidate
Geprüfte PubChem- & CAS-Identität C14H18FNO2 · CAS 1354631-33-6 · CID 52944002
Kalibrierte Lieferform Reines Kristall / Analyse-Pulver (≥98 %)
≥98 % analytische Reinheit geprüft 251.30 g/mol
WHO-, PubMed- & PubChem-Quellen 3 cited records

Rezeptor-Telemetrie & Wirkmechanismus

DAT Dopaminergic Signaling Primary
NET Noradrenergic Signaling Active
SERT Serotonergic Signaling Variable

4F-MPH is a fluorinated analogue of methylphenidate and a dopamine/norepinephrine reuptake inhibitor, not a substrate releaser like amphetamine. Fluorination increases potency relative to methylphenidate, which is why the PsychonautWiki common oral band is only 10–15 mg. The reference IUPAC is the (2R,2'R) threo form, methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate. The subjective feel is focused stimulation, anxiety at the top of the range, and a long residual tail rather than an entactogenic roll.

Biotransformation & Active Metabolites

Like methylphenidate, the ester can be hydrolyzed to the inactive ritalinic-acid analogue. It is not a prodrug of amphetamine and it is not isopropylphenidate.

Zeitliche Pharmakokinetik

Potent, functional NDRI stimulant. Focus and wakefulness, little serotonin warmth, a sharp anxiety edge when pushed, and hours of residual stimulation.

  1. Onset 30–60 minutes
  2. Peak Window 2–4 hours
  3. Total Window 4–8 hours
  4. Residual / Half-Life After-effects 5–10 hours. The ester hydrolysis product is not an active 'second wind'.

Threshold under 5 mg, light 5–10 mg, common 10–15 mg, strong 15–20 mg, heavy above 20 mg. The entire useful span is about 15 mg wide. mucosal exposure common is 8–14 mg and shorter; it is harsher and not required to describe the oral window. A methylphenidate-sized dose is already a heavy 4F-MPH dose.

Quantitatives Wirkungsspektrum (Literaturdaten)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
under 5 mg
Cognitive & Sensory

A small increase in alertness.

Somatic & Autonomic

Slight dry mouth.

Light
5–10 mg
Cognitive & Sensory

Functional focus and wakefulness with little elevated dopaminergic tone.

Somatic & Autonomic

Appetite suppression and a mild pulse increase.

Common Reference
10–15 mg
Cognitive & Sensory

Clear stimulation, task focus, and talkativeness that can tip into scatter.

Somatic & Autonomic

Tachycardia, cold hands, bruxism, and sweating.

Strong
15–20 mg
Cognitive & Sensory

Anxiety, forced wakefulness, and irritable focus rather than better concentration.

Somatic & Autonomic

Pronounced vasoconstriction, tremor, and a long insomnia tail.

Heavy / Toxic Zone
20 mg+
Cognitive & Sensory

Agitation, paranoia, and compulsive repeated exposure.

Somatic & Autonomic

Hypertensive strain, chest discomfort, severe insomnia, and seizure risk with tramadol or an MAOI.

Wechselwirkungsmatrix — Niemals kombinieren

Lebensgefahr — Niemals kombinieren

MAOIs (phenelzine, tranylcypromine, moclobemide, harmala alkaloids)

Blocking monoamine breakdown while a releaser or a catecholamine uptake inhibitor is active can produce a hypertensive crisis and, for the serotonergic members, serotonin toxicity.

25x-NBOMe and 25x-NBOH

Adds extreme vasoconstriction and seizure risk on top of an already raised heart rate and blood pressure.

Tramadol and DXM

Both lower the seizure threshold. Tramadol also adds serotonin reuptake inhibition, which is dangerous with the serotonergic releasers in this set.

Hohes Risiko — Vermeiden

Other stimulants, cocaine, and high-dose caffeine

Additive tachycardia, hypertension, bruxism, and post-session anxiety without restoring a faded peak.

Alcohol, opioids, and benzodiazepines

The stimulant hides sedation. When it drops, the depressant remains.

Vorsicht / Abschwächung

Other phenidates, including isopropylphenidate and methylphenidate

Additive norepinephrine/dopamine reuptake block. IPPH common is 15–25 mg and is not a top-up for 4F-MPH.

Acidic drinks or food changing absorption

May change how fast the oral dose arrives. It does not make a 20 mg dose a light one.

Isomeren- & Strukturvergleich

4F-MPH is the potent fluorinated methylphenidate: common oral 10–15 mg, heavy above 20 mg, 4–8 hours plus a 5–10 hour tail. IPPH is the isopropyl ester, less sharp, common 15–25 mg, total about 3.5–6 hours. Methylphenidate tablet habits are larger than this compound's heavy line. Neither phenidate is an entactogen; 4-FA and 5-MAPB are the wrong family and the wrong interactions.

Stabilität & Lagerung

Form: White, off-white, or pale tan crystalline powder, shards, or clumps as the hydrochloride or another salt. Not a plant blend. · Hydrochloride salts dissolve in water and alcohols. Succinate salts of the benzofurans also dissolve in water but contain less active amine per milligram.

Airtight, cool, dry, and dark. Some salts are hygroscopic and clump. A clump is not a reason to guess the mass.

Cross-Tolerance & Dependence Profile

Stimulant tolerance with cross-tolerance to other NDRIs and amphetamines. Halves over roughly 3–7 days and approaches baseline in 1–2 weeks of abstinence. Psychological dependence and a crash of fatigue and low mood are expected. It is not an opioid withdrawal. Chasing the 2–4 hour peak with a second 10 mg is how the heavy zone is reached.

Analytische & toxikologische Monographie

4F-MPH (methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate; CAS 1354631-33-6, PubChem CID 52944002) is 4-fluoromethylphenidate supplied as pure powder or crystals (C14H18FNO2, 251.30 g/mol). The reference structure is the (2R,2'R) threo isomer. It is a dopamine/norepinephrine reuptake inhibitor, more potent than methylphenidate and not a serotonin releaser. PsychonautWiki oral bands are threshold under 5 mg, light 5–10 mg, common 10–15 mg, strong 15–20 mg, and heavy above 20 mg, over 4–8 hours with 5–10 hours of after-effects. A methylphenidate-sized amount is already heavy here. IPPH is a milder, shorter phenidate and not a milligram match. Do not combine with MAOIs, tramadol, other stimulants, or 25x-NBOMe.

Chemische Struktur und Molekülprofil

4F-MPH (methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate) ist eine Referenzverbindung aus der Stoffklasse Phenethylamin-Derivate mit der Summenformel C14H18FNO2 und einer molaren Masse von 251.3 g/mol. Die Stammverbindung wird unter der CAS-Nummer 1354631-33-6 sowie in der NCBI-PubChem-Datenbank unter CID 52944002 geführt (Standard-InChIKey: XISBAJBPDVRSPG-CHWSQXEVSA-N).

Quellen

Referenztoxikologie und Sicherheitsprofil

Laut dokumentierten Referenzdaten (PubChem / PsychonautWiki, CC BY 4.0) gehört 4F-MPH zur chemischen Klasse Substituted phenidates. Substituiertes Phenethylamin-Derivat; dokumentierte Sicherheitshinweise nennen Wechselwirkungen mit MAO-Hemmern, Tramadol und Lithiumsalzen. Beim Umgang im Labor sind geeignete persönliche Schutzausrüstung und das Sicherheitsdatenblatt (SDB) zu beachten.

Quellen

Analytischer Verwendungszweck und Laborhinweis

Dieses Datenblatt dient ausschließlich der chemischen, analytischen und toxikologischen Dokumentation. Das Material ist nicht für den menschlichen Verzehr bestimmt. Ein Forschungshinweis begründet keinen Rechtsstatus.

Quellen

Dokumentierte Wechselwirkungen und Kontraindikationen

Hohes Risiko / Gefährliche Kombinationen

Unsichere Kombinationen (erhöhtes Risiko)

Ungeklärte Wechselwirkungen (Vorsicht geboten)